D-PLEX 311- Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX In Prevention of Post Abdominal Surgery Incisional Infection(SHIELD I)
Latest Information Update: 09 Dec 2025
At a glance
- Drugs Doxycycline hyclate (Primary) ; Antibacterials
- Indications Surgical wound infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SHIELD I
- Sponsors POLYPID
Most Recent Events
- 12 Nov 2025 According to a POLYPID media release, a face-to-face pre- New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) scheduled for early December
- 17 Sep 2025 According to a POLYPID media release, the company plans to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Surgical wound infections (Prevention) in early 2026.
- 21 Oct 2024 According to a POLYPID media release, today announced a publication in the International Journal of Surgery (IJS), the article highlights the full dataset from the first Phase 3 study of D-PLEX100, from which top-line results were announced in September 2022.